Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial.

BACKGROUND: BI 695501 is an FDA-approved biosimilar to adalimumab reference product (RP). VOLTAIRE-X was a randomized clinical trial to assess outcomes with a biosimilar monoclonal antibody in line with the FDA requirements for designation as an 'interchangeable' biosimilar.
OBJECTIVE: The aim of this study was to assess whether multiple switches between adalimumab RP and BI 695501 lead to equivalent pharmacokinetics and a similar safety and immunogenicity profile compared with continuous adalimumab RP.
METHODS: We conducted a phase III, double-blind, randomized controlled trial between July 19, 2017, and April 16, 2019. There were 49 investigational sites across Europe and North America. Of 323 screened patients with moderate-to-severe chronic plaque psoriasis, 259 were treated with adalimumab RP during the run-in period. Of these, 118 and 120 were randomized to the continuous or switching arms, respectively. Interventions consisted of a run-in period with adalimumab RP 80 mg subcutaneously (SC) on Day 1, then 40 mg SC every other week (EOW) Weeks 2-12. Patients were then randomized to receive adalimumab RP 40 mg EOW Weeks 14-48 (continuous arm) or BI 695501 40 mg Weeks 14 and 16, adalimumab RP 40 mg Weeks 18 and 20, and BI 695501 40 mg EOW Weeks 22 to 48 (switching arm); all interventions were given SC. Primary endpoints were pharmacokinetics parameters, area under the plasma concentration-time curve (AUCτ,30-32) and maximum observed drug plasma concentration (Cmax,30-32), measured after the third switch during the Week 30-32 dosing interval.
RESULTS: 238 patients (mean [standard deviation] age 44.9 [13.8]; 66.0% male) were treated in the switching (n = 118) or continuous arms (n = 120). Adjusted mean Cmax,30-32 was 7.08 and 7.00 μg/mL in the switching and continuous treatment arms, respectively; adjusted mean AUCτ,30-32 was 2025.8 and 1925.9 μg h/mL. Point estimate for mean ratio for AUCτ,30-32 was 105.2% (90.2% confidence interval [CI] 96.6-114.6), and 101.1% (90.2% CI 93.3-109.7) for Cmax,30-32. Both CIs were within a predefined bioequivalence range of 80.0-125.0%. Treatment-emergent adverse events led to discontinuation in 0.8% and 1.7% of patients in the switching and continuous treatment arms, and Psoriasis Area and Severity Index (PASI) scores were highly similar in the two arms across the entire trial period.
CONCLUSIONS: Pharmacokinetic equivalence was demonstrated, with highly similar efficacy and immunogenicity, and comparable safety observed in patients with chronic plaque psoriasis who received either adalimumab RP continuously or who switched between adalimumab RP and BI 695501. TRIAL REGISTRATION: ClinicalTrials.gov: NCT03210259 (registered July 2017); Eudract.ema.europa.eu: 2016-002254-20.

Key Points

Introduction

Monoclonal antibodies targeting tumor necrosis factor-α, including infliximab and adalimumab, have greatly improved outcomes in patients with rheumatic diseases [1-3], psoriasis [4], and inflammatory bowel disease [5]. However, patient access can be limited due to high costs [6, 7]. Biosimilars are defined by the United States (US) Food and Drug Administration (FDA) as biologics that are highly similar to a reference product (RP), with no clinically meaningful differences in terms of safety, purity, and potency, notwithstanding minor differences in clinically inactive components [8]. The availability of biosimilars is intended to increase access to treatment for patients by decreasing cost.

BI 695501 (adalimumab-adbm; Cyltezo®, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany) is a biosimilar to adalimumab RP (Humira®; AbbVie Inc., North Chicago, IL, US). BI 695501 was bioequivalent to adalimumab RP in terms of pharmacokinetics (PK) in a study of healthy volunteers [9]. Subsequently, BI 695501 was shown to have equivalent efficacy and similar safety to adalimumab RP in a phase III randomized controlled trial (RCT) in patients with rheumatoid arthritis [10]. An extension study demonstrated continued similar efficacy and safety in patients receiving BI 695501 for up to 2 years [11]. Based on the extrapolation of indications, BI 695501 received approval from the FDA for use in seven indications not protected by exclusivity for which adalimumab RP is licensed, including chronic plaque psoriasis [12]. Equivalent efficacy and similar safety and immunogenicity of BI 695501 to adalimumab RP were demonstrated in patients with chronic plaque psoriasis in the VOLTAIRE-PSO study [13]. Based on the results from the VOLTAIRE-X RCT that are presented in this article, BI 695501 was approved by the FDA as being ‘interchangeable’ with adalimumab RP [14].

In the US, ‘interchangeability’ is a second regulatory (FDA) approval that allows a biosimilar product to be substituted for the RP without the intervention of the initial prescriber [15]. The first biosimilar to be approved by the FDA as being ‘interchangeable’ was insulin glargine-yfgn (SEMGLEE®) [16]; however, at the time that VOLTAIRE-X was completed, no monoclonal antibodies were approved as being ’interchangeable’ [17]. The FDA criteria for this designation require that a product must have demonstrated biosimilarity to the RP and be expected to produce the same clinical result as the RP in any given patient. Additionally, the risk in terms of safety or diminished efficacy of switching between the biosimilar and the RP should not be greater than the risk of using the RP without switching [15].

In this article, we describe the results from the VOLTAIRE-X RCT, reporting outcomes with adalimumab biosimilar in a trial designed to meet the FDA criteria for ‘interchangeability’ [15].

Methods

Study Design and Participants

VOLTAIRE-X (NCT03210259) was a phase III, double-blind, active comparator RCT conducted at 49 investigational sites in Europe and North America (Fig. 1). The trial design incorporated a 14-week run-in period of treatment with the adalimumab RP followed by a randomized, double-blind, 2-arm period of 34 weeks. A pre-specified blinded interim analysis with sample size reassessment was planned to be performed after approximately 86 patients with evaluable PK data reached their Week 32 endpoints assessment.

Fig. 1

Study design. aAdalimumab RP 80 mg loading dose on Day 1 and then 40 mg/0.8 mL or 40 mg/0.4 mL EOW from Week 2 to Week 12. bFirst PK sampling interval (adalimumab RP only). cBI 695501 40 mg/0.8 mL at Week 14 and Week 16, adalimumab RP 40 mg/0.8 mL EOW at Week 18 and Week 20, and then BI 695501 40 mg/0.8 mL EOW from Week 22 to Week 48. dAdalimumab RP 40 mg/0.8 mL EOW from Week 14 to Week 48. ePrimary endpoints assessment period, and the second PK sampling interval (Week 30–32) in switching (BT) and continuous (BR) arms. BSA body surface area, EOW every other week, PASI psoriasis area and severity index, RP reference product, sPGA Static Physician’s Global Assessment

Patients were aged ≥ 18 and < 80 years at screening with a diagnosis of moderate-to-severe chronic plaque psoriasis. Patients must have had stable disease per the opinion of the investigator for 2 months prior to the first dose of study treatment, with no changes in skin morphology or significant flares at screening and baseline, as well as being considered candidates for systemic therapy or phototherapy. Full inclusion and exclusion criteria are listed in the electronic supplementary material (ESM).

The protocol was approved by the applicable independent ethics committee or institutional review board at each participating site, and the trial was performed in accordance with Good Clinical Practice and the Declaration of Helsinki. Written informed consent was obtained from all patients before their participation.

Randomization

Investigators enrolled patients, and randomization was performed during a standard pre-treatment call using an interactive response technology system. After the 14-week run-in period with adalimumab RP, patients with a ≥ 50% reduction in the Psoriasis Area and Severity Index (PASI50) were randomized 1:1 at Week 14 to either the continuous or switching treatment arms, stratified by level of response (≥ PASI50 to < PASI75, or ≥ PASI75). Patients were randomized sequentially, using the lowest available randomization number. Patients with a < 50% PASI50 response at Week 14 were discontinued from further study treatment and followed only for safety. Blinded third-party personnel administered study treatment. The interactive response technology system ensured that no person directly involved in the conduct of the trial had access to treatment allocation, except for the unblinded pharmacist and the study medication administrator. All personnel involved in trial analyses were unblinded after database lock.

Intervention

The 14-week run-in period consisted of treatment with adalimumab RP (40 mg/0.8 mL or 40 mg/0.4 mL formulation) 80 mg on Day 1, and 40 mg every other week (EOW) during Weeks 2–12, administered subcutaneously (SC). The US-licensed reference product was used across all locations (including those in Europe). Treatment in the switching arm consisted of BI 695501 40 mg (40 mg/0.8 mL formulation) at Weeks 14 and 16, followed by adalimumab RP 40 mg at Weeks 18 and 20, and then BI 695501 40 mg EOW during Weeks 22–48, all administered SC. The continuous treatment arm was adalimumab RP 40 mg EOW during Weeks 14–48. The duration of the run-in period and the number and duration of the switching intervals were aligned with the FDA, as now specified in the FDA guidance regarding study design for demonstration of interchangeability [15].

Clinical and Laboratory Monitoring

PK and immunogenicity were assessed at baseline and Weeks 2, 8, 12, 14, 18, 22, 30, 32, 40, 50, and 58. PK assessments were performed pre-dose at all visits, except for Weeks 50 (end of treatment) and 58 (end of safety follow-up period), with additional sampling 72, 120, 168, and 240 hours after Week 12 and Week 30 dosing. PASI and static Physician’s Global Assessment (sPGA) were assessed at screening, baseline, and Weeks 4, 8, 14, 18, 22, 28, 32, 40, and 50. Adverse events (AEs) were coded using the MedDRA Version 22.1. System organ classes were sorted by internationally agreed European Medicines Agency system organ class and preferred terms.

Outcomes

The primary endpoints were PK parameters area under the plasma concentration–time curve (AUC) and maximum observed drug plasma concentration (Cmax,30–32), measured after the third switch during the Week 30–32 dosing interval. The number and lengths of the switching intervals were in accordance with the FDA requirements [15]. Secondary PK endpoints were minimum observed plasma concentration (Cmin,30–-32) and time to maximum observed plasma concentration (tmax,30–32) assessed during Week 30–32.

Further secondary endpoints included the proportion of patients with PASI75 responses and the proportion of patients with sPGA ≤ 1 (clear or almost clear) at Week 32, in addition to the proportion of patients with antidrug antibodies (ADAs) and neutralizing antidrug antibodies (nAbs) at Week 32. Safety was assessed based on the proportion of patients with treatment-emergent adverse events (TEAEs) after randomization and during the 10-week safety follow-up period. The proportions of patients with TEAEs, serious AEs, AEs of special interest, and injection-site reactions were also assessed.

Sample Size Calculation

An initial sample size of 170 PK-evaluable patients was determined for the primary analysis at Week 32 to provide approximately 90% power, with a one-sided alpha level of 0.049, an assumed treatment difference of 8% (i.e., that the geometric mean ratio would be 92%), and a coefficient of variation of approximately 30% for Cmax,30–32 and AUC, respectively. These assumptions were based on data from a previous study of BI 695501 in healthy participants [9], and on simulations accounting for multiple dosing regimens and baseline PK parameters. It was assumed that approximately 30% of patients would not be evaluable for the primary analysis, due to drop-out or non-evaluable PK readout. Therefore, 240 patients were recommended to be recruited in the trial.

Statistical Analysis

Analyses of the primary and secondary PK endpoints were performed on the PK set (PKS; Suppl. Table 1, see ESM). An ANCOVA model was used to analyze AUCτ,30–32 and Cmax,30–32, which accounted for the (pre-randomization) covariables treatment (switching vs continuous arms), logarithm of PASI improvement (the ratio of PASI response at Week 14 and at Week 1), weight at Week 14, study stage (prior to or after the blinded sample size reassessment), and AUC or Cmax,12–14. The blinded interim analysis was conducted and a significance level of 4.9% was used for the final analysis of the ratios of the means of AUC and Cmax,30–32 across the two arms, which included a two-sided 90.2% confidence interval (CI). Equivalence was concluded if the 90.2% CI for the ratio of means across the two arms was within the bioequivalence range of 80.0–125.0%, as per FDA guidelines [15]. The secondary PK endpoint of Cmin,30–32 was analyzed in the same way as the primary endpoints; however, only the mean ratio and CI were calculated, and no formal comparison to the bioequivalence range was performed. tmax,30–32 was analyzed descriptively.

All efficacy analyses were based on the per-protocol set (Suppl. Table 1, see ESM). Confidence intervals for the differences in the proportions of patients with PASI responses in each arm were obtained using the Wald method. Safety was assessed in the safety evaluation set (treated set), while all patients treated during the run-in period were assessed in the run-in treated set (Suppl. Table 1, see ESM). Safety analyses were descriptive in nature and based on trial period. Immunogenicity assessments were descriptive in nature and were conducted in the treated set and run-in treated set.

Role of the Funding Source

Boehringer Ingelheim was involved in trial design, data collection, data analysis, and data interpretation. The authors had full access to all the data in the trial and had final responsibility for the decision to approve this manuscript for publication.

Results

Participants

In total, 323 patients were screened, and 259 patients were treated with adalimumab RP during the run-in period (Fig. 2). Of these, 238 patients were randomized with 118 assigned to switching and 120 to continuous treatment. The per-protocol set included all 118 patients in the switching arm and 119 (99.2%) in the continuous treatment arm. The pharmacokinetic assessment set included 104 (88.1%) of the patients in the switching arm and 99 (82.5%) of those in the continuous treatment arm. Thirty-two (13.4%) patients discontinued prematurely from randomized treatment with the most common reason being withdrawal of consent. The most common reason for exclusion from the PK analysis set was missed doses, occurring in four patients (3.4%) in the switching arm and ten patients (8.3%) in the continuous arm. The first patient was enrolled on July 19, 2017, and the last patient completed treatment on April 16, 2019. Patient demographics and disease characteristics at baseline were well balanced between the two treatment arms (Table 1).

Fig. 2

CONSORT diagram of patient flow. AE adverse events, RP reference product

Table 1

Patient demographics and disease characteristics

Characteristic	Switching (n = 118)	Continuous (n = 120)	Total (n = 238)
Mean (SD) age at informed consent, years	46.1 (13.95)	43.7 (13.69)	44.9 (13.84)
Gender, n (%)
Male	81 (68.6)	76 (63.3)	157 (66.0)
Female	37 (31.4)	44 (36.7)	81 (34.0)
Ethnicity, n (%)
Hispanic or Latino	18 (15.3)	18 (15.0)	36 (15.1)
Not Hispanic or Latino	100 (84.7)	102 (85.0)	202 (84.9)
Race, n (%)
Asian	2 (1.7)	0 (0.0)	2 (0.8)
Black or African American	2 (1.7)	0 (0.0)	2 (0.8)
Native Hawaiian or other Pacific Islander	1 (0.8)	0 (0.0)	1 (0.4)
White	113 (95.8)	119 (99.2)	232 (97.5)
Other	0 (0.0)	1 (0.8)	1 (0.4)
Mean (SD) weight at baseline/randomization, kg	89.04 (20.94)/89.43 (20.89)	90.22 (20.60)/90.26 (20.51)	89.63 (20.72)/89.85 (20.66)
Mean (SD) BMI at baseline/randomization, kg/m2	29.54 (6.42)/29.67 (6.39)	30.77 (6.72)/30.78 (6.70)	30.16 (6.58)/30.23 (6.55)
Mean (SD) PASI score at baseline/randomization	20.42 (7.57)/3.41 (3.09)	20.54 (7.50)/3.73 (3.48)	20.48 (7.52)/3.57 (3.29)
Mean (SD) sPGA score at baseline/randomization	3.2 (0.42)/1.4 (0.81)	3.3 (0.45)/1.5 (0.90)	3.3 (0.44)/1.4 (0.85)
ADA at baseline, n (%)
Positive	16 (13.6)	8 (6.7)	24 (10.1)
Negative	99 (83.9)	110 (91.7)	209 (87.8)
Not reportable	3 (2.5)	2 (1.7)	5 (2.1)
ADA at randomization, n (%)
Positive	104 (88.1)	103 (85.8)	207 (87.0)
Negative	14 (11.9)	17 (14.2)	31 (13.0)
nAb at baseline, n (%)
Negative	115 (97.5)	118 (98.3)	233 (97.9)
Not reportable	3 (2.5)	2 (1.7)	5 (2.1)
nAb at randomization, n (%)
Positive	52 (44.1)	49 (40.8)	101 (42.4)
Negative	66 (55.9)	71 (59.2)	137 (57.6)

ADA antidrug antibody, BMI body mass index, nAb neutralizing antidrug antibody, PASI Psoriasis Area and Severity Index, SD standard deviation, sPGA Static Physician’s Global Assessment of psoriasis

Pharmacokinetics

For the primary PK endpoints, adjusted mean AUC was 2025.8 and 1925.9 μg h/mL in the switching and continuous treatment arms, respectively, and adjusted mean Cmax,30–32 was 7.08 and 7.00 μg/mL, respectively (Fig. 3). Point estimates for the adjusted mean ratios of switching and continuous treatments for AUC and Cmax,30–32 were 105.2% and 101.1%, respectively. The 90.2% CI ranged from 96.6 to 114.6% and 93.3 to 109.7% for the respective measures; both were within the bioequivalence range of 80.0–125.0%.

Fig. 3

Area under the drug plasma concentration–time curve and maximum observed drug plasma concentration during the dosing interval Week 30–32 (pharmacokinetic seta)b. aAll patients who received study treatment and for whom at least one primary pharmacokinetic parameter was available. bAnalyzed using an ANCOVA model, accounting for the impact of treatment (switching vs continuous arms), logarithm of PASI improvement (the ratio of PASI response at Week 14 and at Week 1), weight at Week 14, stage (prior to or after the blinded sample size reassessment), and AUC or Cmax,12–14. AUC area under the concentration–time curve, CI confidence interval, C maximum observed adalimumab plasma concentration, PASI Psoriasis Area and Severity Index

Adjusted mean Cmin,30–32 was 4.91 μg/mL in the switching arm and 4.58 μg/mL in the continuous arm (point estimate for the ratios of the adjusted mean 107.3%; 90.2% CI 97.3–118.4). Median tmax,30–32 was 72.7 h (interquartile range 71.1–120.0) in the switching arm and 72.3 hours (interquartile range 70.9–120.0) in the continuous arm. Mean plasma concentration–time profiles in the two arms were highly similar over the entire study period (Suppl. Fig. 1, see ESM).

Efficacy

The proportions of patients with PASI75 responses at Week 32 were highly similar between the two arms—switching and continuous (100/118 [84.8%] and 94/119 [79.0%] patients, respectively; difference 5.8%; 90% CI − 2.5 to 14.0). PASI scores over time were highly similar in the two arms across the entire trial period (Suppl. Fig. 2, see ESM).

The proportions of patients with sPGA responses ≤ 1 at Week 32 were highly similar between the switching (83/112 patients [70.3%]) and continuous (77/109 patients [64.7%]) arms (difference 5.6%; 90% CI − 4.4 to 15.6).

Immunogenicity

Throughout the entire trial period, highly similar proportions of patients in the two treatment arms were ADA- or nAb-positive (Suppl. Fig. 3, see ESM). At Week 32, highly similar proportions of patients developed ADAs in the switching (101/112 [90.2%]; median titer 64) and continuous arms (104/110 [94.5%]; median titer 128). Results were highly similar in each arm for nAbs (switching: 46/112 [41.1%]; continuous: 46/110 [41.8%]).

Safety

During the run-in period with adalimumab RP, 103 patients (39.8%) experienced at least one TEAE, the majority of which were not serious (101 patients [39.0%]). Two patients (0.8%) experienced at least one TEAE that led to discontinuation of adalimumab RP, and one patient (0.4%) died (diffuse axonal injury and demyelination—see ESM for details). Twenty-four patients (9.3%) experienced TEAEs during this period, which were only serious in two (0.8%).

Post-randomization, 67 patients (56.8%) in the switching arm and 75 patients (62.5%) in the continuous arm experienced at least one TEAE (Table 2). The proportion of patients with a given TEAE was highly similar in the two treatment arms, except for nasopharyngitis (higher incidence in the switching arm; Suppl. Table 2, see ESM). Treatment-emergent injection-site reactions occurred in three patients (2.5%) in the continuous arm and five patients (4.2%) in the switching arm. Most TEAEs were not serious (139/238; 58.4%).

Table 2

Safety summary post-randomization (safety evaluation set)

AEs, n (%)	Switching (n = 118)	Continuous (n = 120)	Total (n = 238)
At least one TEAE	67 (56.8)	75 (62.5)	142 (59.7)
At least one TEAEa	14 (11.9)	22 (18.3)	36 (15.1)
At least one serious TEAE	5 (4.2)	4 (3.3)	9 (3.8)
At least one non-serious TEAE	67 (56.8)	72 (60.0)	139 (58.4)
At least one serious TEAEa	0 (0.0)	1 (0.8)	1 (0.4)
At least one severe TEAE	3 (2.5)	5 (4.2)	8 (3.4)
At least one TEAE of special interestb	1 (0.8)	0 (0.0)	1 (0.4)
TEAEs leading to discontinuation	1 (0.8)	2 (1.7)	3 (1.3)

AEs adverse events, TEAE treatment-emergent adverse event

All patients who received at least one dose of study treatment in the randomized phase

aInvestigator assessed

bDefined as hepatic injury, anaphylactic reactions, serious infection, or hypersensitivity reactions

In the continuous and switching arms, 22 (18.3%) and 14 (11.9%) patients, respectively, experienced TEAEs that investigators considered related to study treatment. Across both arms, the only treatment-related TEAEs that were reported in ≥ 1% of patients were injection-site erythema (6/238; 2.3%) and arthralgia (3/238; 1.3%).

Fewer than 5% of patients experienced severe TEAEs, AEs of special interest, or TEAEs resulting in treatment discontinuation, with no notable difference between treatment groups. No patients died during the post-randomization treatment period.

Discussion

In VOLTAIRE-X, primary and secondary PK endpoints were equivalent and clinical outcomes were highly similar in patients with moderate-to-severe chronic plaque psoriasis who received either adalimumab RP continuously or in those who switched three times between BI 695501 and adalimumab RP. For the primary PK endpoints of Cmax,30–32 and AUC, the mean ratio point estimates were close to 100%, with 90.2% CIs well within the bioequivalence range of 80.0–125.0% [15, 18]. These results were supported by the secondary PK endpoints, in addition to previous studies that demonstrated highly similar PK of BI 695501 to adalimumab RP [10, 11, 19]. Although analyses of clinical efficacy were descriptive in nature, the proportions of patients with PASI75 and sPGA ≤ 1 responses at Week 32 were highly similar between the switching and continuous treatment arms. PASI responses were comparable to other studies that compared adalimumab RP with other candidate biosimilars, as well as in the VOLTAIRE-PSO study [13, 20]. Analyses of ADAs and of nAbs demonstrated comparable immunogenicity in both arms. Safety results were similar between the two arms, with no new safety signals noted. On the basis of these data, BI 695501 was approved by the FDA as being ‘interchangeable’ with adalimumab RP, becoming the first monoclonal biosimilar to be granted this designation [14]. Based on extrapolation of indications, these results provide rheumatologists, dermatologists, and gastroenterologists with data to support the substitution of BI 695501 for adalimumab RP in patients with any of the seven indications for which BI 695501 is approved [12].

While there has been speculation that multiple switches might increase immunogenicity [21], this RCT indicated highly similar immunogenicity in patients who underwent multiple treatment switches between adalimumab RP and BI 695501 compared with those who received continuous treatment with adalimumab RP. A high-sensitivity assay was used in this RCT to detect ADAs and nAbs, which resulted in positive rates of > 90% and > 41%, respectively, in both arms. Similar high levels of immunogenicity have been reported in many trials of adalimumab RP and of other candidate adalimumab biosimilars [22]. However, higher levels of immunogenicity result from the recent use of more sensitive assays than were used during the development of adalimumab RP [22, 23], but are not indicative of a change in the clinical impact of ADAs (increased drug clearance and lower drug exposure [24]), as was confirmed by the demonstration of PK bioequivalence and similar levels of immunogenicity in the two treatment arms in this RCT.

The ‘interchangeable’ designation is unique to the US regulatory system, with no equivalent in Europe and other regions. An FDA-approved interchangeable biosimilar can be substituted for its reference product by a pharmacist without requiring prior approval from the prescriber (where permitted by state law) [15]. This designation of interchangeability is only applicable to the individual biosimilar approved by the FDA as interchangeable; pharmacist-level substitution can occur between the interchangeable biosimilar and the RP, but not between the RP and its other biosimilars, or between the interchangeable biosimilar and other biosimilars of the RP.

This RCT of a biosimilar monoclonal antibody satisfies the new FDA requirements for demonstrating interchangeability with an RP, although the guidance for interchangeability had not yet been published at the time the protocol was being developed [15]. This RCT assessed PK parameters as primary endpoints, and immunogenicity, efficacy, and safety were secondary endpoints, consistent with FDA guidance for demonstrating interchangeability [15]. Accordingly, three switches between adalimumab RP and BI 695501 were included in the switching arm. This RCT was also conducted in an indication considered sensitive for the assessment of PK bioequivalence, as adalimumab is administered as monotherapy in patients with plaque psoriasis [25]. In contrast, patients with rheumatoid arthritis frequently receive concomitant treatment with methotrexate, which could potentially reduce the immunogenicity of adalimumab and alter its PK.

A final strength of this RCT was that it included a ‘run-in’ period to account for inter-patient variability of adalimumab exposure [26] and to generate an additional covariate for the ANCOVA model used for the analysis of the primary PK endpoints.

Three switches were mandated in the switching arm, as is now specified in the FDA guidance document [15]. In clinical practice, patients may be subjected to more than three switches between the RP and a biosimilar, be treated with one agent for a longer duration before switching, be switched between different available biosimilars, or from a biosimilar back to the RP. However, it is not possible to assess all of the potential scenarios that might occur in clinical practice in a single RCT. A further minor limitation of this RCT was the reduced precision of tmax and Cmax assessments as a consequence of sparse PK sampling, due to clinical feasibility of sampling in an outpatient setting. Nonetheless, a possible small bias in Cmax was not expected to affect the assessment of the primary PK endpoints and the conclusion of bioequivalence, as both arms were affected in the same way.

Conclusion

VOLTAIRE-X met FDA requirements for demonstrating interchangeability of a biosimilar monoclonal antibody with its RP. Based on equivalent PK and highly similar efficacy, immunogenicity, and safety in the two treatment arms, BI 695501 has been approved by the FDA as being ‘interchangeable’ with adalimumab RP, becoming the first monoclonal biosimilar to be granted this designation [14].

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 398 kb)

Are pharmacokinetic equivalence and similar efficacy, safety, and immunogenicity maintained in patients with chronic plaque psoriasis who switched multiple times between adalimumab reference product (RP) and BI 695501?

Switching three separate times between adalimumab RP and BI 695501 resulted in pharmacokinetic equivalence, highly similar efficacy and immunogenicity outcomes, and comparable safety compared with patients on continuous adalimumab RP.

These findings support the interchangeability of BI 695501 with adalimumab RP.